We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Cardinal Health (CAH) Up 2.5% Since Its Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Cardinal Health, Inc. (CAH - Free Report) . Shares have added about 2.5% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is CAH due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
Cardinal Health reported third-quarter fiscal 2018 adjusted earnings of $1.39 per share, which missed the Zacks Consensus Estimate of $1.51. Adjusted earnings fell 9% year over year.
Revenues increased 6% on a year-over-year basis to almost $33.63 billion and edged past the Zacks Consensus Estimate of $33.60 billion.
Segmental Analysis
Pharmaceutical Segment
Pharmaceutical revenues increased 5% to $29.72 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical Distribution customers.
However, the segment witnessed expiration of a large, mail-order customer contract along with the divestiture of the company's China distribution business.
Pharmaceutical witnessed a 3% decline in profits to $596 million, thanks to generic pharmaceutical pricing.
Medical Segment
Revenues in the segment improved 15% to $3.92 billion, primarily on higher contributions from new and existing customers along with the acquisition of the Patient Recovery business. Medical segment profits increased 34% to $199 million.
Margin Analysis
Gross Profit increased 10.7% year over year to $1.91 billion.As a percentage of revenues, gross margin expanded 30 basis points (bps) to 5.7% of net revenues.
Guidance
The company slashed guidance for fiscal 2018 adjusted earnings per share to $4.85-$4.95.
The downside was caused by the company's effective tax rate associated with the Cordis business.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There have been seven revisions lower for the current quarter.
Currently, CAH has a nice Growth Score of B, though it is lagging a bit on the momentum front with a C. The stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is primarily suitable for value investors while also being suitable for those looking for growth and to a lesser degree momentum.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. It's no surprise CAH has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Cardinal Health (CAH) Up 2.5% Since Its Last Earnings Report?
It has been about a month since the last earnings report for Cardinal Health, Inc. (CAH - Free Report) . Shares have added about 2.5% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is CAH due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
Cardinal Health reported third-quarter fiscal 2018 adjusted earnings of $1.39 per share, which missed the Zacks Consensus Estimate of $1.51. Adjusted earnings fell 9% year over year.
Revenues increased 6% on a year-over-year basis to almost $33.63 billion and edged past the Zacks Consensus Estimate of $33.60 billion.
Segmental Analysis
Pharmaceutical Segment
Pharmaceutical revenues increased 5% to $29.72 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical Distribution customers.
However, the segment witnessed expiration of a large, mail-order customer contract along with the divestiture of the company's China distribution business.
Pharmaceutical witnessed a 3% decline in profits to $596 million, thanks to generic pharmaceutical pricing.
Medical Segment
Revenues in the segment improved 15% to $3.92 billion, primarily on higher contributions from new and existing customers along with the acquisition of the Patient Recovery business. Medical segment profits increased 34% to $199 million.
Margin Analysis
Gross Profit increased 10.7% year over year to $1.91 billion.As a percentage of revenues, gross margin expanded 30 basis points (bps) to 5.7% of net revenues.
Guidance
The company slashed guidance for fiscal 2018 adjusted earnings per share to $4.85-$4.95.
The downside was caused by the company's effective tax rate associated with the Cordis business.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There have been seven revisions lower for the current quarter.
Cardinal Health, Inc. Price and Consensus
Cardinal Health, Inc. Price and Consensus | Cardinal Health, Inc. Quote
VGM Scores
Currently, CAH has a nice Growth Score of B, though it is lagging a bit on the momentum front with a C. The stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is primarily suitable for value investors while also being suitable for those looking for growth and to a lesser degree momentum.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. It's no surprise CAH has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.